Syk to death

Blood

Volumn 113, Issue 11, 2009, Pages 2371-

  Bergsagel, P Leif ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; B LYMPHOCYTE RECEPTOR; BREAKPOINT CLUSTER REGION PROTEIN; IDIOTYPE MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MYC PROTEIN; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; R 406; UNCLASSIFIED DRUG;

ANTIGEN BINDING; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER REGRESSION; CELL LINE; CELL SURFACE; CLINICAL FEATURE; ENZYME ACTIVITY; FOLLICULAR LYMPHOMA; HELICOBACTER PYLORI; HUMAN; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; LYMPHOMA; MUTANT; NONHODGKIN LYMPHOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STOMACH LYMPHOMA;

EID: 63849174958     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-12-191510     Document Type: Note

References (4)

1. Meeker T, Lowder J, Cleary ML, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med. 1985;312:1658-1665.
2. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330:1267-1271.
3. Young RM, Hardy IR, ClarkeRL, et al. Mousemodels ofnon-Hodgkin lymphomarevealSyk as animportant therapeutictarget. Blood. 2009;113:2508-2516.
4. Friedberg JW, Sharman J, Schaeffer-Cutillo J, et al. Tamatinib fosdium (TAMF), an oral syk inhibitor, has significant clinical activity in B-cell Non- Hodgkin's Lymphoma (NHL). Ann Oncol. 2008;19: iv115-iv116.